Annual EBITDA:
$7.51M+$157.61M(+105.00%)Summary
- As of today, ESPR annual EBITDA is $7.51 million, with the most recent change of +$157.61 million (+105.00%) on December 31, 2024.
- During the last 3 years, ESPR annual EBITDA has risen by +$229.65 million (+103.38%).
- ESPR annual EBITDA is now at all-time high.
Performance
ESPR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
N/ASummary
- ESPR quarterly EBITDA is not available.
Performance
ESPR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
TTM EBITDA:
N/ASummary
- ESPR TTM EBITDA is not available.
Performance
ESPR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
ESPR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +105.0% | - | - |
| 3Y3 Years | +103.4% | - | - |
| 5Y5 Years | +108.5% | - | - |
ESPR EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +103.4% | ||||
| 5Y | 5-Year | at high | +103.4% | ||||
| All-Time | All-Time | at high | +103.4% |
ESPR EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $7.12M(+132.3%) | -$35.34M(+11.4%) |
| Mar 2025 | - | -$22.07M(-402.4%) | -$39.87M(-173.2%) |
| Dec 2024 | $7.51M(+105.0%) | -$4.39M(+72.5%) | $54.47M(+84.0%) |
| Sep 2024 | - | -$16.00M(-718.0%) | $29.60M(+63.6%) |
| Jun 2024 | - | $2.59M(-96.4%) | $18.09M(+184.1%) |
| Mar 2024 | - | $72.27M(+347.0%) | -$21.51M(+84.9%) |
| Dec 2023 | -$150.11M(+14.9%) | -$29.26M(-6.4%) | -$142.30M(+8.5%) |
| Sep 2023 | - | -$27.51M(+25.7%) | -$155.46M(+8.3%) |
| Jun 2023 | - | -$37.01M(+23.7%) | -$169.47M(+8.2%) |
| Mar 2023 | - | -$48.52M(-14.4%) | -$184.69M(-3.2%) |
| Dec 2022 | -$176.35M(+20.6%) | -$42.42M(-2.2%) | -$179.00M(+6.8%) |
| Sep 2022 | - | -$41.52M(+20.5%) | -$192.06M(+6.8%) |
| Jun 2022 | - | -$52.23M(-21.9%) | -$206.13M(-10.7%) |
| Mar 2022 | - | -$42.84M(+22.8%) | -$186.28M(+17.6%) |
| Dec 2021 | -$222.14M(-84.6%) | -$55.48M(+0.2%) | -$226.12M(+15.0%) |
| Sep 2021 | - | -$55.59M(-71.7%) | -$266.05M(+8.5%) |
| Jun 2021 | - | -$32.38M(+60.8%) | -$290.85M(-125.1%) |
| Mar 2021 | - | -$82.67M(+13.4%) | -$129.18M(-6.9%) |
| Dec 2020 | -$120.33M(-35.6%) | -$95.41M(-18.7%) | -$120.85M(-43.4%) |
| Sep 2020 | - | -$80.39M(-162.2%) | -$84.30M(-21.1%) |
| Jun 2020 | - | $129.29M(+273.9%) | -$69.59M(+72.6%) |
| Mar 2020 | - | -$74.34M(-26.3%) | -$254.12M(-173.9%) |
| Dec 2019 | -$88.73M(+56.0%) | -$58.86M(+10.4%) | -$92.78M(+1.8%) |
| Sep 2019 | - | -$65.68M(-18.9%) | -$94.49M(-19.1%) |
| Jun 2019 | - | -$55.24M(-163.5%) | -$79.31M(-12.5%) |
| Mar 2019 | - | $87.00M(+243.6%) | -$70.49M(+65.5%) |
| Dec 2018 | -$201.52M | -$60.58M(-20.0%) | -$204.32M(-12.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$50.49M(-8.8%) | -$182.38M(-2.7%) |
| Jun 2018 | - | -$46.42M(+0.9%) | -$177.56M(-1.6%) |
| Mar 2018 | - | -$46.83M(-21.2%) | -$174.74M(-3.6%) |
| Dec 2017 | -$166.53M(-124.1%) | -$38.63M(+15.4%) | -$168.72M(-5.9%) |
| Sep 2017 | - | -$45.67M(-4.8%) | -$159.31M(-21.3%) |
| Jun 2017 | - | -$43.59M(-6.8%) | -$131.29M(-28.8%) |
| Mar 2017 | - | -$40.82M(-39.7%) | -$101.96M(-34.3%) |
| Dec 2016 | -$74.33M(-51.6%) | -$29.22M(-65.6%) | -$75.90M(-26.8%) |
| Sep 2016 | - | -$17.65M(-23.7%) | -$59.84M(-8.7%) |
| Jun 2016 | - | -$14.27M(+3.3%) | -$55.06M(-3.5%) |
| Mar 2016 | - | -$14.76M(-12.1%) | -$53.20M(-6.8%) |
| Dec 2015 | -$49.03M(-36.4%) | -$13.17M(-2.3%) | -$49.80M(-8.4%) |
| Sep 2015 | - | -$12.87M(-3.7%) | -$45.96M(-7.5%) |
| Jun 2015 | - | -$12.41M(-9.2%) | -$42.74M(-8.1%) |
| Mar 2015 | - | -$11.37M(-21.9%) | -$39.55M(-9.7%) |
| Dec 2014 | -$35.95M(-43.3%) | -$9.32M(+3.4%) | -$36.06M(+1.1%) |
| Sep 2014 | - | -$9.65M(-4.7%) | -$36.47M(-13.2%) |
| Jun 2014 | - | -$9.21M(-16.9%) | -$32.21M(-40.1%) |
| Mar 2014 | - | -$7.88M(+19.0%) | -$23.00M(-52.1%) |
| Dec 2013 | -$25.08M(-147.9%) | -$9.73M(-80.2%) | -$15.12M(-180.2%) |
| Sep 2013 | - | -$5.40M(-150.7%) | -$5.40M(-150.7%) |
| Dec 2012 | -$10.12M(-0.5%) | - | - |
| Mar 2012 | - | -$2.15M | -$2.15M |
| Dec 2011 | -$10.06M(+64.0%) | - | - |
| Dec 2002 | -$27.95M(-5.5%) | - | - |
| Dec 2001 | -$26.48M(-3.7%) | - | - |
| Dec 2000 | -$25.52M(-118.4%) | - | - |
| Dec 1999 | -$11.68M | - | - |
FAQ
- What is Esperion Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Esperion Therapeutics, Inc.?
- What is Esperion Therapeutics, Inc. annual EBITDA year-on-year change?
- What is the all-time high quarterly EBITDA for Esperion Therapeutics, Inc.?
- What is the all-time high TTM EBITDA for Esperion Therapeutics, Inc.?
What is Esperion Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of ESPR is $7.51M
What is the all-time high annual EBITDA for Esperion Therapeutics, Inc.?
Esperion Therapeutics, Inc. all-time high annual EBITDA is $7.51M
What is Esperion Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, ESPR annual EBITDA has changed by +$157.61M (+105.00%)
What is the all-time high quarterly EBITDA for Esperion Therapeutics, Inc.?
Esperion Therapeutics, Inc. all-time high quarterly EBITDA is $129.29M
What is the all-time high TTM EBITDA for Esperion Therapeutics, Inc.?
Esperion Therapeutics, Inc. all-time high TTM EBITDA is $54.47M